Overview of Glutamatergic Dysregulation in Central Pathologies
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
As the major excitatory neurotransmitter in the mammalian central nervous system, glutamate plays a key role in many central pathologies, including gliomas, psychiatric, neurodevelopmental, and neurodegenerative disorders. Post-mortem and serological studies have implicated glutamatergic dysregulation in these pathologies, and pharmacological modulation of glutamate receptors and transporters has provided further validation for the involvement of glutamate. Furthermore, efforts from genetic, in vitro, and animal studies are actively elucidating the specific glutamatergic mechanisms that contribute to the aetiology of central pathologies. However, details regarding specific mechanisms remain sparse and progress in effectively modulating glutamate to alleviate symptoms or inhibit disease states has been relatively slow. In this report, we review what is currently known about glutamate signalling in central pathologies. We also discuss glutamate’s mediating role in comorbidities, specifically cancer-induced bone pain and depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670 · cited 1×
“cells into the bone microenvironment disrupts this homeostasis, and may contribute to CIBP [209–211].”
BackgroundVos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 1×
“Notably, cancer and depression are both established to be pro-inflammatory pathologies [188–190].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 1×
“In addition to the iGluRs, metabotropic glutamate receptors (mGluRs) indirectly modulate postsynaptic ion channels, consist of G-protein coupled receptors (mGluR1-8), which are further subdivided according to their activation by either (±)1-amino-cyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD) or L(+)-2-amino-4-…”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“In rats, administration of ketamine caused rapid activation of the mammalian target of rapamycin (mTOR) pathway, which is involved in synaptogenesis, and blocking mTOR signalling effectively blocked ketamine-induced synaptogenesis [56].”
BackgroundThe HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., Copeland, N. G., Sisodia, S. S., Rothstein, J. D., Borchelt, D. R., Price, D. L., et al. (1997) · Neuron · doi:10.1016/s0896-6273(00)80272-x · Cited by 1,341 · cited 6×
“SOD1 transgenic mice [114] and rats [115] also show a reduction in the glutamate transporter EAAT2.”
BackgroundInfluentialAndrade, L., Caraveo‐anduaga, J. J., Berglund, P., Bijl, R. V., Graaf, R. D., Vollebergh, W., Dragomirecka, E., Kohn, R., Keller, M., Kessler, R. C., et al. (2003) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.138 · Cited by 1,068 · cited 1×
“Major depressive disorder (MDD) is the most common mood disorder, with a lifetime prevalence of ~8%–12% [40].”
BackgroundCorrection of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 1×
“investigating ketamine’s efficacy in treatment-resistant bipolar depression have yielded similar results to those seen in unipolar depression studies, with rapid and robust antidepressant effects achieved after a single-dose [67,68].”
ResultEffectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064135 · Cited by 937 · cited 1×
“depression [62–64].”
Geddes, J. R., & Miklowitz, D. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60857-0 · Cited by 848
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846 · cited 1×
“For example, results from magnetic resonance spectroscopy (MRS) suggest decreased levels of glutamate in the prefrontal cortex (PFC) and anterior cingulate cortex (ACC) of patients with MDD [47,48].”
ResultZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811 · cited 1×
“investigating ketamine’s efficacy in treatment-resistant bipolar depression have yielded similar results to those seen in unipolar depression studies, with rapid and robust antidepressant effects achieved after a single-dose [67,68].”
ResultCotter, D., Mackay, D., Landau, S., Kerwin, R., & Everall, I. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.545 · Cited by 766
Duman, R. S., & Voleti, B. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.004 · Cited by 714
Geddes, J. R., Burgess, S., Hawton, K., Jamison, K., & Goodwin, G. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.217 · Cited by 661
Cotter, D. (2002) · Cerebral Cortex · doi:10.1093/cercor/12.4.386 · Cited by 634 · cited 1×
“Deficiencies in glial cell density and neuronal size have also been reported in the PFC, amygdala, and ACC of depressed subjects [53–55].”
BackgroundThe Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568 · cited 1×
“observations that NMDAR antagonists, such as ketamine and phencyclidine (PCP), induce psychotomimetic symptoms in both human subjects and animal models, suggesting that NMDARs are hypofunctional in SZ [90–93].”
BackgroundMolecular Mechanisms of Fragile X Syndrome: A Twenty-Year Perspective
Santoro, M. R., Bray, S. M., & Warren, S. T. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132457 · Cited by 528 · cited 2×
“Glutamate dysregulation has been well characterized in certain psychiatric, neurodevelopmental, and neurodegenerative disorders, such as schizophrenia, fragile X syndrome, and epilepsy [7,8].”
BackgroundGABAergic interneuron origin of schizophrenia pathophysiology
Nakazawa, K., Zsiros, V., Jiang, Z., Nakao, K., Kolata, S., Zhang, S., & Belforte, J. E. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.022 · Cited by 498 · cited 1×
“To explain the paradoxical observations of NMDAR hypofunction and glutamatergic excitotoxicity in SZ, animal studies have suggested that NMDAR hypofunction at GABA-ergic inhibitory interneurons is sufficient to induce SZ symptoms [96].”
Deficient glutamate tranport is associated with neurodegeneration in Alzheimer's disease
Masliah, E., Hansen, L., Alford, M., Deteresa, R., & Mallory, M. (1996) · Annals of Neurology · doi:10.1002/ana.410400512 · Cited by 476
The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases
Lo, M., Wang, Y., & Gout, P. W. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21366 · Cited by 399 · cited 12×
“The prevalence of glutamate dysregulation in central pathologies is perhaps not surprising, given its ubiquitous presence in the CNS and its influence as an important neurotransmitter and cell-signalling molecule under normal and pathological conditions.”
BackgroundInfluentialChapter 6 Glutamate receptors and the induction of excitotoxic neuronal death
Choi, D. W. (1994) · Progress in Brain Research · doi:10.1016/s0079-6123(08)60767-0 · Cited by 385
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes
Hamidi, M., Drevets, W. C., & Price, J. L. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.006 · Cited by 369 · cited 1×
“Deficiencies in glial cell density and neuronal size have also been reported in the PFC, amygdala, and ACC of depressed subjects [53–55].”
BackgroundGlutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344 · cited 1×
“Despite region-specific decreases in glutamate, total brain levels of glutamate are elevated in the CSF of OCD patients [82,83].”
BackgroundLI, S., MALLORY, M., ALFORD, M., TANAKA, S., & MASLIAH, E. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00008 · Cited by 343
Correlation between plasma levels of glutamate, alanine and serine with severity of depression
Mitani, H., Shirayama, Y., Yamada, T., Maeda, K., Ashby, C. R., & Kawahara, R. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.036 · Cited by 332
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309 · cited 1×
“More recently, single doses of ketamine have been robustly demonstrated to alleviate depressive symptoms for up to one week, even in treatment-resistant patients [42–44].”
BackgroundDuric, V., Banasr, M., Stockmeier, C. A., Simen, A. A., Newton, S. S., Overholser, J. C., Jurjus, G. J., Dieter, L., & Duman, R. S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000016 · Cited by 304 · cited 6×
“In addition to clinical observations, post-mortem hippocampal samples from depressed subjects were shown to contain decreased expression of genes that encode subunits of AMPARs [49].”
BackgroundInfluentialThe glutamate hypothesis of schizophrenia: evidence from human brain tissue studies
Hu, W., MacDonald, M. L., Elswick, D. E., & Sweet, R. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12547 · Cited by 286 · cited 1×
“However, studies examining transcriptional control of glutamate receptors and transporters have yielded largely mixed results, with few studies following up mRNA results with protein expression analysis [98].”
ResultIncreased cerebrospinal fluid glutamine levels in depressed patients
Levine, J., Panchalingam, K., Rapoport, A., Gershon, S., McClure, R. J., & Pettegrew, J. W. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00284-x · Cited by 240 · cited 6×
“Despite region-specific decreases in glutamate, total brain levels of glutamate are elevated in the CSF of OCD patients [82,83].”
BackgroundInfluentialGigante, A. D., Bond, D. J., Lafer, B., Lam, R. W., Young, L. T., & Yatham, L. N. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.01033.x · Cited by 226
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Niciu, M. J., Roiser, J. P., & Zarate, C. A. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568041 · Cited by 224
Anti-Brain Autoantibodies and Altered Excitatory Neurotransmitters in Obsessive–Compulsive Disorder
Bhattacharyya, S., Khanna, S., Chakrabarty, K., Mahadevan, A., Christopher, R., & Shankar, S. K. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.77 · Cited by 172 · cited 1×
“Despite region-specific decreases in glutamate, total brain levels of glutamate are elevated in the CSF of OCD patients [82,83].”
BackgroundNovel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Strawn, J. R., Chu, W.-J., Whitsel, R. M., Weber, W. A., Norris, M. M., Adler, C. M., Eliassen, J. C., Phan, K. L., Strakowski, S. M., & DelBello, M. P. (2013) · Neuropsychobiology · doi:10.1159/000347090 · Cited by 44 · cited 1×
“A recent MRS study in adolescents with generalized anxiety disorder (GAD) found that the ratio of glutamate to creatine (Glu/Cr) in the ACC correlated with severity of anxiety scores [76].”
Backgroundβ-Amyloid Enhances Glial Glutamate Uptake Activity and Attenuates Synaptic Efficacy
Ikegaya, Y., Matsuura, S., Ueno, S., Baba, A., Yamada, M. K., Nishiyama, N., & Matsuki, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203764200 · Cited by 39 · cited 1×
“Astrocyte cultures treated with amyloid-beta peptide (Aβ) showed increased extracellular glutamate clearance and decreased glutamatergic synaptic function in cultured neurons, suggesting redistribution in EAAT1 to the astrocyte membrane [137].”
Background
Cited by
Glutamatergic Signaling Along The Microbiota-Gut-Brain Axis
Baj, A., Moro, E., Bistoletti, M., Orlandi, V., Crema, F., & Giaroni, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061482 · Cited by 331
Bosi, A., Banfi, D., Bistoletti, M., Giaroni, C., & Baj, A. (2020) · International Journal of Tryptophan Research · doi:10.1177/1178646920928984 · Cited by 221
Gulyaeva, N. V. (2021) · Biochemistry (Moscow) · doi:10.1134/s0006297921060031 · Cited by 54
Chlorpyrifos-induced dysregulation of synaptic plasticity in rat hippocampal neurons
Zhou, W., Zhang, C., Wang, P., Deng, Y., Dai, H., Tian, J., Wu, G., & Zhao, L. (2023) · Journal of Environmental Science and Health, Part B · doi:10.1080/03601234.2023.2171236 · Cited by 14
Metadata
- Authors
- Miladinovic, T., Nashed, M., & Singh, G.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2015-11-11
- Volume
- 5
- Issue
- 4
- Pages
- 3112-3141
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W2139374843
- Cited by
- 137
- References
- 42
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.